Fatty Acid

Butyrate

Butyric acid

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

2 to 6 g/day (protocol dependent)

watchEffect Window

days to weeks in tested protocols

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Butyrate is a short-chain fatty acid used for gut barrier and inflammatory support.

Human evidence is strongest in ulcerative colitis and IBS-style symptom settings. Brain, stress, and broader immune claims are still exploratory and should not be treated as established general-health effects.

SCFA signaling and HDAC-related pathways support mechanistic plausibility. Human outcome evidence is population- and protocol-specific.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Fear-memory modulation in selected human psychobiology protocols
  • Select inflammatory/metabolic outcomes in targeted studies

Secondary Outcomes

  • GI symptom modulation dependent on tolerance
  • No validated broad cognitive performance enhancement

Safety

Contraindications and Interactions

Contraindications

  • Severe GI intolerance
  • Pregnancy or lactation without clinician oversight
  • Severe hepatic/renal instability

Side effects

  • Bloating and gas
  • Nausea and loose stool
  • Mild abdominal cramping

Interactions

  • Multi-SCFA/prebiotic stacks (possible tolerance burden)
  • Immunomodulatory therapies (clinical monitoring advised)

Avoid if

  • Active bowel obstruction
  • History of severe butyrate intolerance
  • Unstable medical conditions without clinician oversight

Evidence

Study-level References

butyrate-SRC-001Randomized, triple-blind, placebo-controlled trial
Sourceopen_in_new

Dalile B, Fuchs A, La Torre D, Vervliet B, Van Oudenhove L, Verbeke K. Colonic butyrate administration modulates fear memory but not the acute stress response in men: A randomized, triple-blind, placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2024;131:110939. doi:10.1016/j.pnpbp.2024.110939. PMID:38199487.

Population: Healthy adult men.

Dose protocol: Colonic release capsules delivering approximately 5.28 g/day for 1 week

Key findings: Modest subjective fear-memory modulation. No major acute stress response change.

Notes: Healthy-cohort and stress-task specificity may limit generalization.

Paper content

This triple-blind RCT in 71 healthy men used pH-dependent colon-delivery capsules to administer 5.28 g/day butyrate for one week. The intervention increased serum butyrate and altered subjective fear-memory responses, but it did not change subjective or neuroendocrine acute stress responses. That distinction matters because it narrows the psychobiology claim. Butyrate alone may affect selected fear-memory processing, but it does not reproduce the broader stress-response effects previously seen with mixed short-chain-fatty-acid interventions.

butyrate-SRC-002Randomized, double-blind controlled trial
Sourceopen_in_new

Bouter KEC, et al. Effects of oral butyrate supplementation on inflammatory potential of circulating peripheral blood mononuclear cells in healthy and obese males. Sci Rep. 2019;9(1):775. doi:10.1038/s41598-018-37246-7. PMID:30692581.

Population: Healthy lean and metabolic syndrome adults

Dose protocol: ~4 g/day sodium butyrate for 4 weeks

Key findings: Directional reduction in selected trained-immune responses.

Notes: Small sample and endpoint-specific effects rather than broad cognitive endpoints.

Paper content

Directional reduction in selected trained-immune responses.

butyrate-SRC-003RCT
Sourceopen_in_new

Karlowicz K, Lewandowski K, Kaniewska MA, et al. Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis. Med Sci Monit. 2025;31. doi:10.12659/MSM.948912. PMID:41422374.

Population: Adults with active mild-to-moderate ulcerative colitis

Dose protocol: Microencapsulated sodium butyrate as add-on therapy

Key findings: Improvement in remission-related outcomes vs control.

Notes: Disease-specific population. Adjunctive protocol limits generalization to healthy users.

Paper content

This multicenter double-blind RCT of 98 patients with mild-to-moderate ulcerative colitis found that microencapsulated sodium butyrate (600 mg/day) as add-on therapy for 8 weeks significantly improved clinical remission (31.4%), clinical improvement (51%), and biochemical remission (42.2%) compared to placebo.

butyrate-SRC-004Double-blind randomized controlled trial
Sourceopen_in_new

Firoozi D, et al. Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. Lipids Health Dis. 2024;23(1):216. doi:10.1186/s12944-024-02203-z. PMID:39003477.

Population: Adults with active ulcerative colitis

Dose protocol: Butyrate-containing SCFA intervention

Key findings: Favorable directionality on inflammatory and selected symptom endpoints.

Notes: Condition-specific cohort with mixed endpoint set.

Paper content

Favorable directionality on inflammatory and selected symptom endpoints.

butyrate-SRC-005Randomized controlled trial
Sourceopen_in_new

Banasiewicz T, et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013;15(2):204-209. doi:10.1111/j.1463-1318.2012.03152.x. PMID:22738315.

Population: Adults with IBS

Dose protocol: Microencapsulated sodium butyrate vs control

Key findings: Reduced abdominal pain frequency in treated group.

Notes: Older single-indication trial and formulation-specific effect.

Paper content

Reduced abdominal pain frequency in treated group.

butyrate-SRC-006Prospective randomized placebo-controlled trial
Sourceopen_in_new

Goldiș A, Dragomir R, Mercioni MA, Sirca D, Goldiș C, Enatescu I, Olariu L, Belei O. Clinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory Bowel Disease. Life (Basel). 2025;15(6):902. doi:10.3390/life15060902. PMID:40566555.

Population: Children and adolescents with newly diagnosed active ulcerative colitis or Crohn's disease receiving conventional treatment.

Dose protocol: 150 mg/day sustained-release sodium butyrate for 12 weeks as adjunctive therapy

Key findings: Remission occurred in 81.8% of the sodium butyrate group versus 47.7% with placebo, with larger CRP and fecal calprotectin improvements.

Notes: Stronger modern disease-specific RCT that raises confidence for adjunctive IBD use, not for general wellness claims.

Paper content

This pediatric adjunctive-care trial tested sustained-release sodium butyrate in 88 children and adolescents with newly diagnosed inflammatory bowel disease. At 12 weeks, remission was more common with sodium butyrate than placebo, and both CRP and fecal calprotectin improved more strongly in the butyrate arm. No adverse effects were reported. The study strengthens the disease-specific gut-inflammatory evidence for butyrate, while still limiting generalization to healthy users or to non-IBD indications.

Guides

Setup

Help